CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus
CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus
复制标题
DOI：
10.1007/s10238-015-0348-3
复制
发表时间：
2016-05-01
影响因子：
4.6
通讯作者：
Paiva, Artur
中科院分区：
文献类型：
--
作者：
Henriques, Ana;Silva, Isabel;Paiva, Artur
系统性红斑狼疮（SLE）临床表现多样，病程难以预测，临床治疗困难。需要生物标志物和诊断辅助手段在治疗前、治疗中和治疗后监测SLE疾病活动和严重程度。我们进行了这项研究，以寻找独特的表型模式，在每个外周血（PB）B细胞亚群，能够区分SLE患者与非活动性疾病与SLE患者与活动性疾病与对照组通过使用自动人口分离器（APS）的可视化策略。从41例SLE患者和28例年龄和性别匹配的对照组中收集PB。我们使用APS软件工具中实施的主成分分析法分析了PB B细胞亚群上的细胞表面标志物（在试管中CD 20/CD 27/CD 19/CD 45/CD 38/CD 81/BAFFR组合）表达。总之，我们的分析表明，活动性SLE可以区分非活动性SLE的基础上，单管分析，重点是在过渡B细胞中的CD 38，CD 81和BAFFR的表达减少。对B细胞亚群免疫表型谱的聚类分析突出了过渡性B细胞上的疾病特异性异常，其作为疾病活动的有希望的替代标记物出现。需要通过更大的样本和对患者的前瞻性随访进行进一步验证。
In view of its heterogeneous presentation and unpredictable course, clinical management of systemic lupus erythematosus (SLE) is difficult. There is a need for biomarkers and diagnostic aids to monitor SLE disease activity and severity prior to, during and after treatment. We undertook this study to search for unique phenotypic patterns in each peripheral blood (PB) B cell subset, capable of distinguishing SLE patients with inactive disease versus SLE patients with active disease versus controls by using an automated population separator (APS) visualization strategy. PB was collected from 41 SLE patients and 28 age- and gender-matched controls. We analyzed the cell surface markers (in a tube CD20/CD27/CD19/CD45/CD38/CD81/BAFFR combination) expression on PB B cell subsets using principal component analysis, implemented in the APS software tool. Overall, our analysis indicates that active SLE can be distinguished from inactive SLE on the basis of a single tube analysis, focused on the decreased expression of CD38, CD81 and BAFFR in transitional B cells. The cluster analysis of immunophenotypic profiles of B cell subsets highlighted disease-specific abnormalities on transitional B cells that emerge as promising surrogate markers for disease activity. Further validation is needed with larger samples and prospective follow-up of patients.